Cargando…

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms

SIMPLE SUMMARY: Approximately 10–20% of pancreatic cancer patients will have a mutation in their DNA, passed on in families, that contributes to the development of their pancreatic cancer. These mutations are important in that they effect the biology of the disease as well as contribute to sensitivi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devico Marciano, Naomie, Kroening, Gianna, Dayyani, Farshid, Zell, Jason A., Lee, Fa-Chyi, Cho, May, Valerin, Jennifer Goldstein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140002/ https://www.ncbi.nlm.nih.gov/pubmed/35626055 http://dx.doi.org/10.3390/cancers14102453

Ejemplares similares

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
por: Singh, Amisha, et al.
Publicado: (2021)

Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach
por: Cho, May T., et al.
Publicado: (2022)

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
por: Brazel, Danielle, et al.
Publicado: (2022)

Pancreatic Cancer: Beyond Brca Mutations
por: Ricci, Vincenzo, et al.
Publicado: (2022)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations
por: Chahla, Elie, et al.
Publicado: (2016)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

BRCA mutated pancreatic cancer: A change is coming
por: Rosen, Michael N, et al.
Publicado: (2021)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial
por: Senthil, Maheswari, et al.
Publicado: (2023)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
por: Golan, T, et al.
Publicado: (2014)

Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance
por: Martínez-Galán, Joaquina, et al.
Publicado: (2021)

Rethinking the Antibiotic Discovery Paradigm
por: Hancock, Robert E.W.
Publicado: (2015)

Primary Spinal Infections in Patients With Hematologic Immunocompromising Conditions: A Systematic Literature Review
por: Devico Marciano, Naomie, et al.
Publicado: (2023)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
por: Kaakour, Dalia, et al.
Publicado: (2022)

Medullary carcinoma of the duodenum treated with pembrolizumab: a case report
por: Liu, Louisa, et al.
Publicado: (2023)

Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
por: Hu, Yunlong, et al.
Publicado: (2020)

Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
por: Lowery, Maeve A.
Publicado: (2019)

Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
por: Takeuchi, Shoko, et al.
Publicado: (2018)

BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer
por: Kondo, Tomohiro, et al.
Publicado: (2020)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

ASO Author Reflections: Challenges of Circulating Tumor DNA in the Management of Gastrointestinal Peritoneal Carcinomatosis
por: Sullivan, Brittany G., et al.
Publicado: (2022)

Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
por: Boursi, Ben, et al.
Publicado: (2023)

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation
por: Pujol, Pascal, et al.
Publicado: (2022)

Prevalence of BRCA1 and BRCA2 Mutations in Korean Breast Cancer Patients
por: Ahn, Sei Hyun, et al.
Publicado: (2004)

BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study
por: Zhen, David B., et al.
Publicado: (2014)

The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
por: Seeber, Andreas, et al.
Publicado: (2020)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

BRCA1 and BRCA2 mutations in Scotland and Northern Ireland
Publicado: (2003)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Prediction of carrying a BRCA1 or BRCA2 mutation
por: Lee, Kyung-Hun
Publicado: (2023)

Clinically Meaningful Use of Blood Tumor Markers in Oncology
por: Holdenrieder, Stefan, et al.
Publicado: (2016)

Screening and verification of potential gene targets in esophageal carcinoma by bioinformatics analysis and immunohistochemistry
por: Wen, Pingwu, et al.
Publicado: (2022)

Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix
por: Kaakour, Dalia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vfit5ho66v61unnbtnf2gkq017